文献速递神经肿瘤

CDKN2A/B状态与形态学在诊断WHO 4级IDH突变型星形细胞瘤中的对比:临床相关性何在?

CDKN2A/B status versus morphology in diagnosing WHO grade 4 IDH-mutated astrocytomas: what is the clinical relevance?
PubMed 文献 · J Neurooncol · 2025-05-20

研究纳入Sahlgrenska大学医院和TCGA数据库共90例IDH突变型星形细胞瘤WHO 4级患者,按诊断标准分为纯合CDKN2A/B缺失组、形态学组和联合组。中位生存期4.1年(95%CI 3.0-5.3);纯合CDKN2A/B缺失组与形态学组生存期相当(5.2年 vs 5.3年),联合组生存期显著更短(2.8年,p=0.006)。结论认为各亚组特征相似,但联合标准患者预后更差。

要点

  • IDH突变型星形细胞瘤WHO 4级中位生存期4.1年(95%CI 3.0-5.3)。
  • 纯合CDKN2A/B缺失组与形态学组生存期相当(5.2年 vs 5.3年)。
  • 联合CDKN2A/B缺失和形态学标准组生存期显著更短(2.8年,p=0.006)。

核心结论

  • IDH突变型星形细胞瘤WHO 4级不同亚组特征相似,但肿瘤同时符合纯合CDKN2A/B缺失和形态学标准的患者预后更差。

研究设计与样本

  • 研究纳入Sahlgrenska大学医院和TCGA数据库的IDH突变型星形细胞瘤WHO 4级患者,共90例(本地队列n=35,TCGA队列n=55)。
  • 按诊断标准分为三组:纯合CDKN2A/B缺失组、形态学组(坏死和/或微血管增生)、联合组(同时符合纯合CDKN2A/B缺失和形态学4级标准)。

主要发现

  • 全部患者中位生存期为4.1年(95%CI 3.0-5.3)。
  • 纯合CDKN2A/B缺失组与形态学组生存期相当(5.2年 vs 5.3年)。
  • 联合组生存期显著更短(2.8年,p=0.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the 2021 WHO classification system for central nervous system tumors, the diffuse glioma subgroup IDH-mutated (IDHm) astrocytomas WHO grade 4 was introduced. The diagnosis can be based upon molecular or histopathological morphological criteria. Here we explore whether phenotype and survival of IDHm astrocytomas WHO grade 4 differed across the criteria used for diagnosis. METHODS: Patients with IDHm astrocytoma, WHO grade 4, were included from Sahlgrenska University Hospital and TCGA database. We created three subgroups based upon the criteria for diagnosis of WHO grade 4; (1) homozygous CDKN2A/B deletion; (2) morphological (necrosis and/or microvascular proliferation); (3) combined subgroup with both homozygous CDKN2A/B deletion and morphological grade 4 criteria. RESULTS: We included 90 patients (local cohort, n = 35, TCGA cohort, n = 55) with IDHm astrocytoma, WHO grade 4. The median survival was 4.1 years (95% CI 3.0-5.3). Survival was comparable when the diagnosis was based on homozygous CDKN2A/B deletion and on morphological WHO grade 4 criteria (5.2 vs. 5.3 years). However, in the combined subgroup, survival was significantly shorter (2.8 years, p = 0.006). CONCLUSION: The different subgroups of IDHm astrocytoma WHO grade 4 share similar characteristics. Patients whose tumors exhibit combined criteria have worse prognosis.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lipatnikova A, Kling T, Dénes A, et al. CDKN2A/B status versus morphology in diagnosing WHO grade 4 IDH-mutated astrocytomas: what is the clinical relevance? J Neurooncol. 2025. PMID: 40392514. doi:10.1007/s11060-025-05078-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。